We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
NGAL in trans-catheter aortic valve implantation on and off RenalGuard.
- Authors
Sadon, Sapir; Arbel, Yaron; Banai, Ariel; Rozenfeld, Keren-Lee; Taieb, Phillipe; Hochstadt, Aviram; Shacham, Yacov; Banai, Shmuel; Finkelstein, Ariel; Merdler, Ilan
- Abstract
Introduction: Acute kidney injury (AKI) is a well-known complication post invasive cardiac procedures. RenalGuard system has been shown to reduce the risk of AKI in high-risk patients by evacuating iodine-based contrast material rapidly. Neutrophil gelatinase-associated lipocalin (NGAL) is a glycoprotein stored in granules of mature neutrophils and is released to the blood stream due to acute tubular damage. This report examined the biomarker as a sub study of the randomized sham control study REDUCEAKI in the setting of Trans-Aortic Valve Implantation (TAVI). Methods: Venous blood was drawn from 27 patients. Blood was drawn at designated time intervals: before the procedure, after 12 hours and after 24 hours. Patients were randomly allocated to active versus sham RenalGuard activity. Results: There was no difference between baseline and 24 hours levels in NGAL values (ng/mL) in the sham group (median 70.3 IQ 21.5, 176.6) versus the active group (median 46.9, IQR 1.3, 127.7) (P = 0.259). There was also no association between NGAL and clinical complications. Conclusion: Forced diuresis with matched hydration does not prevent AKI in patients undergoing TAVI and measuring NGAL correlates with these findings.
- Subjects
AORTIC valve; ACUTE kidney failure; HEART valve prosthesis implantation; BIOMARKERS
- Publication
Signa Vitae, 2021, Vol 17, Issue 4, p55
- ISSN
1334-5605
- Publication type
Article
- DOI
10.22514/sv.2021.048